



AAVBC

AMERICAN ACADEMY OF VALUE BASED CARE

Renal Cancer

Quick Reference Guide

2026

Table of Contents

1. CLINICAL SNAPSHOT	3
HCC/RAF V28 Mapping	4
2. RECOGNITION AND DIAGNOSIS	6
Diagnostic Tests Covered Under Medicare Part B (Older Adults, At-Risk Population)	6
Subtle Early Signs in Older Adults (>65)	8
Geriatric Risk Factors	9
Diagnostic Thresholds	10
Staging Systems	12
Clues to Dig Deeper	17
Key Differentials in Elderly	17
Comorbidity Screening	19
3. MEAT DOCUMENTATION ESSENTIALS	21
Clinical Documentation Elements	22
Reframing Common Documentation Shortcuts	22
4. TREATMENT AND REFERRAL QUICK GUIDE	23
Therapy Escalation Snapshot	24
NCCN/ASCO/AUA-Aligned Treatment by Stage and Patient Profile	25
Non-Pharmacologic Care and Supportive Interventions	26
Medication Safety and Key Interactions	27
When to Refer	28
Follow-Up Timing	30
Comorbidity Management – Primary Care Role	31
Cost-Smart Options	32
Patient Education and Adherence	34
Quality Metrics Tie-In	35
5. CODING REMINDERS AND CASE EXAMPLES	37
Coding Specificity	37
Annual Clinical Review and Confirmation	38
Good Documentation — EHR Tips	39
Brief Case Examples	40
REFERENCES	41

1 CLINICAL SNAPSHOT

Definition: Renal cell carcinoma (RCC) is a malignancy arising from the renal tubular epithelium and accounts for the large majority of adult kidney cancers.¹ In the Medicare population it is predominantly a disease of **silent presentation**: more than **60%**¹ of cases are discovered incidentally on abdominal imaging ordered for unrelated reasons, and the classic triad of flank pain, hematuria, and a palpable mass now occurs in fewer than **10%** of patients.^{1,2} **Clear cell RCC** is the most common histology (**70-80%** of RCC), followed by papillary (**10-15%**) and chromophobe (**3-5%**) subtypes; each carries distinct biology and treatment implications.¹ Urothelial carcinoma of the renal pelvis is a **separate disease with a** distinct histology and treatment pathway, and is coded under **C65** rather than **C64**.^{2,3} Peak incidence falls in the **65-74** age band, placing RCC squarely within primary-care and geriatric oncology practice.¹

ICD-10 Codes:

Active RCC of the kidney parenchyma is reported with **laterality-specific codes**:³ **C64.1** (right kidney) and **C64.2** (left kidney); **C64.9** (unspecified laterality) should be used only when laterality is **genuinely undocumented** after review of imaging and operative reports. Renal pelvis tumors (urothelial, not RCC) use **C65.1** (right) and **C65.2** (left) = a distinct anatomic site and histology that is **commonly miscoded as C64**. Metastatic spread to the kidney is captured with **C79.0-9** secondary-neoplasm codes, and every confirmed metastatic site is coded separately (for example **C78.00** lung, **C79.51** bone, **C78.7** liver, **C79.31** brain) in addition to the primary **C64.x** code. Presenting hematuria is documented with **R31.0** (gross) or **R31.21** (asymptomatic microscopic). **Z85.528** (personal history of kidney malignancy) is reserved for patients who have **completed treatment with no evidence of disease**; it must not be used while a patient is **on adjuvant therapy or under active surveillance**, where the active **C64.x** code applies.^{3,4}

Prevalence and Burden: An estimated **~81,000** new kidney cancer diagnoses are expected in the United States for 2025, with approximately **735,000 people** living with a prior kidney cancer diagnosis as of January 1, 2025.⁵ SEER data show that RCC incidence has been increasing at approximately **1.1% annually** (95% CI: 0.6%-1.5%) from 2008 to 2019, with projected continued increases from **6.92 per 100,000** (2015-2019) to **9.59 per 100,000** by 2040-2044.⁶ Peak incidence occurs between ages **60 and 70 years**, with the highest age-standardized incidence rates in individuals aged **70-84 years**.^{1,7} About **49%** of U.S. kidney cancer diagnoses occur in adults aged **65 and older**, and approximately 67% of kidney cancer survivors are aged ≥ 65 .^{1,5} At presentation, **70%** of cases are **Stage I** and **11%** are **Stage IV**.¹ Five-year relative survival is **stage-dependent**: approximately **93%** for localized disease, **75%** for regional disease, and **17-18%** for distant (Stage IV) disease.⁸ The male-to-female ratio is approximately **3:2**.¹ Because incidence rises steeply with age, most disease is found **incidentally** (37-61% of cases), and modifiable risk factors such as hypertension, obesity, and smoking are shared with conditions managed in routine primary care, RCC detection and management are increasingly a **shared primary-care responsibility**.¹

AAVBC Knowledge Hub Premium Content Access

Continue reading your guide
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time